Benzinga's Top Upgrades - Core Laboratories (NYSE:CLB)

Analysts at Cantor Fitzgerald upgraded

Aetna IncAET

from Hold to Buy. The price target for Aetna has been raised from $100 to $140. Aetna shares closed at $117.75 on Thursday. Analysts at Cowen & Company upgraded

FMC CorpFMC

from Market Perform to Outperform. The price target for FMC has been lowered from $60 to $51. FMC shares closed at $38.79 on Thursday. Analysts at JP Morgan upgraded

The Valspar CorpVAL

from Neutral to Overweight. The price target for Valspar has been raised from $82 to $83. Valspar shares closed at $74.91 on Thursday. Credit Suisse upgraded

Dillard's, Inc.

DDS

to Neutral. The price target for Dillard's has been lowered from $100 to $95. Dillard's shares closed at $92.30 on Thursday. Raymond James upgraded

Goldman Sachs BDC IncGSBD

from Market Perform to Outperform. Goldman Sachs BDC shares closed at $20.22 on Thursday. Analysts at RBC Capital upgraded

Core Laboratories N.V. CLB

from Sector Perform to Outperform. The price target for Core Laboratories has been raised from $125 to $130. Core Laboratories shares closed at $108.74 on Thursday. UBS upgraded

PPL CorpPPL

from Neutral to Buy. The price target for PPL has been lowered from $34 to $33. PPL shares closed at $30.79 on Thursday.

Market News and Data brought to you by Benzinga APIs